Загрузка...
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...
Сохранить в:
| Опубликовано в: : | Ther Adv Hematol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7874350/ https://ncbi.nlm.nih.gov/pubmed/33613931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989586 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|